Stay updated with breaking news from Alain Herrera. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Onward Therapeutics SA (Onward Therapeutics), a global biotechnology company focused on developing innovative immunotherapies for cancer treatment, today announced that the phase 1 clinical trial of OT-A201 (Study No. A20101), a first-in-class bispecific antibody targeting two immune checkpoints is in progress.
PARIS and CAMBRIDGE, Mass., Nov. 06, 2023 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – “Nanobiotix” or the “Company”), a late-clinical...
EPALINGES, Switzerland and MONTPELLIER, France, June 20, 2022 /PRNewswire/ -- Onward Therapeutics SA (Onward Therapeutics) and Emercell SAS (Emerc...
Election of board members and auditor The nomination committee proposes re-election of Magnus Björsne, Robert Marchesani, Lennart Jeansson, Anna Belfrage, Alain Herrera,... | April 12, 2022
Headed by the successful biotech entrepreneur Grace Yeh, Onward Therapeutics pursues a buy and build strategy with the goal to identify and develop innovative medicines for the treatment of cancer. The company which was founded in 2020 and is based at Biopôle has now closed the first contracts with two biotech start-ups. Onward Therapeutics acquires licenses for potential development candidates and investing in their partners with platform technologies. The company is led by an experienced team.Grace Yeh, President and CEO of Onward Therapeutics was Founder, President and Chief Executive Of...